Aliases:This biomarker is also known as:
- small inducible cytokine A11,
- small inducible cytokine subfamily A (Cys-Cys), member 11 (eotaxin),
- eosinophil chemotactic protein,
- chemokine (C-C motif) ligand 11,
- C-C motif chemokine 11,
From NCBI Gene: This antimicrobial gene is one of several chemokine genes clustered on the q-arm of chromosome 17. Chemokines form a superfamily of secreted proteins involved in immunoregulatory and inflammatory processes. The superfamily is divided into four subfamilies based on the arrangement of the N-terminal cysteine residues of the mature peptide. This chemokine, a member of the CC subfamily, displays chemotactic activity for eosinophils, but not mononuclear cells or neutrophils. This eosinophil-specific chemokine is thought to be involved in eosinophilic inflammatory diseases such as atopic dermatitis, allergic rhinitis, asthma and parasitic infections. [provided by RefSeq, Sep 2014]
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
No additional data available.
Ninety biomarkers were measured using a series of multiplexed immunoassays and results analyzed by the EDRN data management center splitting the cases and controls into training and validation sets, excluding subjects with DCIS or atypical hyperplasia from the training phase. We found little evidence that any of these markers can discriminate women with invasive cancer from those with benign breast conditions.
CCL11 signaling plays an important role in proliferation and invasion of ovarian carcinoma cells. Circulating levels of CCL11 in sera of patients with ovarian cancer were significantly lower than those in healthy women or women with breast, lung, liver, pancreatic, or colon cancer. Cultured ovarian carcinoma cells absorbed soluble CCL11, indicating that absorption by tumor cells could be responsible for the observed reduction of serum level of CCL11 in ovarian cancer. Postoperative CCL11 levels in women with ovarian cancer negatively correlated with relapse-free survival. Ovarian tumors overexpressed three known cognate receptors of CCL11, CC chemokine receptors (CCR) 2, 3, and 5. Strong positive correlation was observed between expression of individual receptors and tumor grade. CCL11 potently stimulated proliferation and migration/invasion of ovarian carcinoma cell lines. The growth-stimulatory effects of CCL11 were likely associated with activation of extracellular signal-regulated kinase 1/2, MEK1, and STAT3 phosphoproteins and with increased production of multiple cytokines, growth factors, and angiogenic factors. Inhibition of CCL11 signaling by the combination of neutralizing antibodies against the ligand and its receptors significantly increased sensitivity to cisplatin in ovarian carcinoma cells.
Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. CCL11 alone was not a strong predictor.
No associated publications found.
- HGNC entry for CCL11 from Genenames
- KEGG entry for CCL11 from Genome.jp
- Entrez entry for CCL11 all NCBI Databasese
- Human GEO Profiles for CCL11 from NCBI GEO Profiles
- Human Geo Datasets containing term CCL11 from NCBI GEO Datasets
- GWAS Study Datasets containing gene CCL11 from GWAS
- Human Single Nucleotide Polymorphisms info for CCL11
- Human Gene(s) with 'CCL11' as Gene Name/Alias
- Human Gene RefSeq for CCL11 from NCBI
- UniProtKB/Swiss-Prot entry for CCL11 from Uniprot
- Human Protein RefSeq for CCL11 from NCBI
- FDA web page describing approval of CCL11
|UniProt Accession #:||P51671|
|Mutated Sites Count:||23|
|Associated Pubmed ID Count||4|
|Affected Protein Function Sites Count:||4|